Abstract:Background: Hereditary angioedema (HAE) is a rare condition marked by swelling episodes in various body parts, including the extremities, upper airway, face, intestinal tract, and genitals. Long-term prophylaxis (LTP), prescribed to control recurring HAE attacks, is integral to its management. Previously, attenuated androgens (AAs) were the only oral LTP options. However, in 2020, berotralstat, an oral plasma kallikrein inhibitor, was approved in the United States. A 2018 survey of adults with HAE type I or type II showed that almost all the patients who used prophylactic HAE medication preferred oral treatment (98%) and felt that it fit their lifestyle better than injectable treatment (96%). Still, guidelines lack consensus on transitioning patients from AAs to alternative oral prophylactic therapy. Objective: This paper aims to share expert insights and patient feedback on transitioning from AAs to berotralstat, an alternative oral prophylactic therapy, from the perspective of clinicians with extensive experience in treating patients with HAE. Methods: A panel of five HAE specialists convened for a virtual half-day roundtable discussion in April 2023. Results: Discussions about transitioning from AAs to berotralstat were prompted by routine consultations, patient inquiries based on independent research, ineffective current treatment, or worsening AA-related adverse effects. For patients who switched from AAs, the physicians reported that the decision was influenced by the alternative therapy's ability to prevent HAE attacks, its safety, and the once-daily administration schedule. All expert panel members identified fewer AA-related adverse effects; better quality of life; and less severe, shorter, and less frequent HAE attacks as clinical or patient goals they hoped to achieve through the treatment switch. Conclusion: The emergence of new, highly specific LTP drugs for HAE calls for the development of comprehensive recommendations and guidelines for transitioning from AAs to alternative oral prophylactic therapy. The expert panel highlighted key factors to consider during the development of such guidelines.

[Long-term prophylactic therapy combined with on-demand therapy for the control of hereditary angioedema--Comment on the 2021 edition of the international WAO/EAACI guideline for the management of hereditary angioedema]

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus

An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy

Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group

Advent of oral medications for the treatment of hereditary angioedema

Hereditary angioedema: current therapeutic management and future approaches

The current situation of hereditary angioedema patients in Germany: results of an online survey

Consensus on treatment goals in hereditary angioedema: A global Delphi initiative

Expert Perspectives on Hereditary Angioedema: Key Areas for Advancements in Care across the Patient Journey

Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches

The Future of Therapeutic Options for Hereditary Angioedema

Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema

The natural course of hereditary angioedema in a Chinese cohort

Hereditary angioedema with normal C1 esterase inhibitor: Current paradigms and clinical dilemmas

Understanding the Impact of Long-Term Prophylaxis Switches for Patients With Hereditary Angioedema

Summary and future of medicine for hereditary angioedema

Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema

New Therapeutics for Allergic Airway Diseases

Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study

An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema